The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients
The MATTERS trial demonstrates that WBHT at 41.50°C, delivered with the TempoCure device, is a safe and well-tolerated treatment for advanced malignancies, particularly in patients with refractory metastatic PDAC. These findings support the integration of WBHT with standard chemotherapy regimens, paving the way for future efficacy trials aimed at improving therapeutic outcomes in challenging cancer populations.
Authors
- T. Chapelle (ORCID: https://orcid.org/0000-0002-6923-2278)
- R. Dankerlui
- Lien Van den Bossche (ORCID: https://orcid.org/0000-0002-7987-6181)
- Eke van Zwol (ORCID: https://orcid.org/0000-0002-3152-8903)
- Vera Saldien (ORCID: https://orcid.org/0000-0002-5151-8999)
- Luigi Brancato (ORCID: https://orcid.org/0000-0002-3396-5445)
- Johannes Bogers (ORCID: https://orcid.org/0000-0001-9107-132X)
- Oleg Rudenko (ORCID: https://orcid.org/0000-0002-1295-3218)
- Peter Vueghs (ORCID: https://orcid.org/0000-0002-9421-037X)
- Timon Vandamme (ORCID: https://orcid.org/0000-0003-3701-5305)
- Dirk Ysebaert (ORCID: https://orcid.org/0000-0002-3350-6994)
- Ivana Gorbašlieva (ORCID: https://orcid.org/0000-0003-2276-379X)
- Johan Van den Bossche (ORCID: https://orcid.org/0000-0002-5498-6368)
- Tine logghe
- Gaëlle Boulet
- Marc Peeters
Institutions
- University of Antwerp (BE)
- Antwerp University Hospital (BE)
- Vlaamse Vereniging voor Obstetrie en Gynaecolo (BE)
- Icometrix (Belgium) (BE)
- AZ Sint-Lucas (BE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0660
- Primary Topic
- Ultrasound and Hyperthermia Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitair Ziekenhuis Antwerpen